Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist.
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
By reverse transcriptase polymerase chain reaction on messenger RNA from human polymorphonuclear cells, we have isolated a sequence identical to the cDNA coding for intracellular interleukin 1 receptor antagonist (icIL-1ra), but containing an additional in-frame 63-bp sequence located three codons downstream of the translation start of icIL-1ra. This additional sequence is inserted between the first and second exon of the intracellular form, the latter of which is colinear with part of the first exon of the secreted form of IL-1ra. The additional sequence is coded by an extra exon located 2 kb downstream the first icIL-1ra-specific exon. The complementary DNA sequence of the alternatively spliced form of icIL-1ra shows that the predicted protein differs from classical icIL-1ra in the NH2 terminus by insertion of a leaderless sequence of 21 amino acids rich in glycine and glutamic acid residues. Transcripts coding for this new form of icIL-1ra were detected in activated fibroblasts, keratinocytes, and at low levels in myelomonocytic cells. The recombinant protein expressed in COS cells had an apparent molecular mass in sodium dodecyl sulfate polyacrylamide gel electrophoresis of 25 kD compared to 22 kD of classical icIL-1ra, and was mostly intracellular. The ability of this new form of icIL-1ra to inhibit IL-1 activity, in terms of induction of E-selectin and human immunodeficiency virus replication, was comparable to that of classical icIL-1ra. We propose to refer to this new form of icIL-1ra as icIL-1ra type II.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122 · cited 1×
“Finally, IL-1 is the only cytokine for which a polypeptide receptor antagonist (IL-lra) has been described (5-7).”
BackgroundCarter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601 · cited 2×
“Secreted IL-lra (slL-lra) contains a classical 25-amino acid leader peptide giving a mature protein of 152 amino acids (6, 7).”
Background
Cited by
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 749
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M., & Iwakura, Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1463 · Cited by 611
“Three isoforms of IL-1ra protein are synthesized by alternative splicing from a single gene; one is a secreted form with a signal peptide (sIL-1ra), and the other two exist intracellularly (icIL-1raI and icIL-1raII) (11, 12).”
BackgroundNeutrophil-Derived Proteins: Selling Cytokines by the Pound
Cassatella, M. A. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60791-9 · Cited by 560
Regulation of serum amyloid A protein expression during the acute-phase response
JENSEN, L. E., & WHITEHEAD, A. S. (1998) · Biochemical Journal · doi:10.1042/bj3340489 · Cited by 411
A primer on cytokines: sources, receptors, effects, and inducers
Curfs, J. H., Meis, J. F., & Hoogkamp-Korstanje, J. A. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.742 · Cited by 317
“This cytokine, which strongly resembles IL-1, completely lacks an agonistic effect in vitro and in vivo (53, 55, 144).”
BackgroundArterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene
Nicklin, M. J. H., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.303 · Cited by 317
Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice.
Hirsch, E., Irikura, V. M., Paul, S. M., & Hirsh, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11008 · Cited by 316
Debets, R., Timans, J. C., Homey, B., Zurawski, S., Sana, T. R., Lo, S., Wagner, J., Edwards, G., Clifford, T., Menon, S., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1440 · Cited by 286
Hack, C. E., Aarden, L. A., & Thus, L. G. (1997) · Advances in Immunology · doi:10.1016/s0065-2776(08)60597-0 · Cited by 280
Bird, S., Zou, J., Wang, T., Munday, B., Cunningham, C., & Secombes, C. J. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00028-x · Cited by 266
Holtkamp, G. M., Kijlstra, A., Peek, R., & de Vos, A. F. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00017-3 · Cited by 254
Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis
Dewberry, R., Holden, H., Crossman, D., & Francis, S. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.2394 · Cited by 227
MERHISOUSSI, F., KWAK, B., MAGNE, D., CHADJICHRISTOS, C., BERTI, M., PELLI, G., JAMES, R., MACH, F., & GABAY, C. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.01.008 · Cited by 200
“The icIL-1Ra2 mRNA possesses an additional exon between icIL-1Ra1 and sIL-1Ra first exons [26].”
BackgroundThe Role of IL‐1 and IL‐1Ra in Joint Inflammation and Cartilage Degradation
Jacques, C., Gosset, M., Berenbaum, F., & Gabay, C. (2006) · Vitamins & Hormones · doi:10.1016/s0083-6729(06)74016-x · Cited by 196
Garlanda, C., Anders, H.-J., & Mantovani, A. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.06.001 · Cited by 165
Self-citationBUGEON, L., & DALLMAN, M. J. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.supplement_3.15tac5 · Cited by 94
Terui, T., Hirao, T., Sato, Y., Uesugi, T., Honda, M., Iguchi, M., Matsumura, N., Kudoh, K., Aiba, S., & Tagami, H. (1998) · Experimental Dermatology · doi:10.1111/j.1600-0625.1998.tb00332.x · Cited by 89
“also reported the existence of three splice variants of IL-1ra (35).”
BackgroundDynamic Regulation of Proinflammatory Cytokines
Watkins, L. R., Nguyen, K. T., Lee, J. E., & Maier, S. F. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_10 · Cited by 67
Kanangat, S., Postlethwaite, A. E., Higgins, G. C., & Hasty, K. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700097 · Cited by 36
Martin, P., Palmer, G., Rodriguez, E., Palomo, J., Lemeille, S., Goldstein, J., & Gabay, C. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901074 · Cited by 19
“corresponding protein has not yet been described (14).”
Background
Metadata
- Authors
- Muzio, M., Polentarutti, N., Sironi, M., Poli, G., De Gioia, L., Introna, M., Mantovani, A., & Colotta, F.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1995-08-01
- Volume
- 182
- Issue
- 2
- Pages
- 623-628
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2104254580
- Cited by
- 121
- References
- 2
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.